Axsome Therapeutics (NASDAQ: AXSM) reported Q3 EPS of ($0.25), $0.33 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $259.7 million versus the consensus estimate of $252.7 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.